Kuehnle AgroSystems Closes Series B Financing to Commercialise World-First Dark Fermentation Natural Astaxanthin
Key Insights
Kuehnle AgroSystems (search) (KAS) has closed a multi-million-dollar Series B financing led by IVC to accelerate commercial production of sustainable natural astaxanthin.
The financing follows the world's first successful demonstration of natural astaxanthin oleoresin production via proprietary dark fermentation at industrially relevant scale.
The global astaxanthin market is valued at approximately US$2 billion and is forecast to grow at 15% annually, driven by salmon aquaculture and nutraceutical demand.
Kuehnle AgroSystems (search) (KAS), an algal biotechnology company headquartered in Honolulu, has announced the successful close of a multi-million-dollar Series B financing round. The investment, led by Ichthus Venture Capital (search) (IVC) with continued participation from existing investors S2G Investments (search) and Hatch Blue (search) alongside new investor Dest EOOD (search), is designed to accelerate the company's transition from technology development to commercial production and sales of sustainable natural astaxanthin.
The financing follows what the company describes as a landmark technical achievement: in collaboration with manufacturing partner Biorea (search), KAS successfully demonstrated — for the first time anywhere in the world — the production of natural astaxanthin in oleoresin using proprietary dark fermentation technology at an industrially relevant scale. This breakthrough establishes the technical foundation for what the company anticipates will be a step-change in the cost of production of sustainable, natural astaxanthin.
"This financing validates both our technology and our commercial strategy," said Dr Claude Kaplan, Chief Executive Officer of Kuehnle AgroSystems (search). "Earlier this year we achieved something many believed impossible — the world's first production of natural astaxanthin oleoresin through dark fermentation. Together with our manufacturing partner, Biorea (search), and our strategic development partner, Corbion (search), we have demonstrated that fermentation can become a commercially viable route to producing one of aquaculture's and nutraceutical's most important ingredients."
Market opportunity and demand drivers
The global astaxanthin market is valued at approximately US$2 billion and is forecast to grow at 15% annually over the coming decade. Demand is being driven by two converging trends: the continued expansion of global salmon aquaculture, where astaxanthin is an essential feed ingredient, and rapid growth in the premium nutraceutical market, where natural astaxanthin is increasingly recognised as one of the world's most potent antioxidants.
In salmon aquaculture, astaxanthin serves a dual purpose. Beyond providing the characteristic pink colour consumers expect, it is a critical nutrient that supports fish health, fertility, stress tolerance, immune function and overall production performance. As global salmon production continues to increase, the industry is simultaneously seeking more sustainable and resilient ingredient supply chains. KAS's fermentation platform offers the potential to provide premium natural astaxanthin with significantly lower environmental impact, improved supply security and a pathway to substantially lower production costs than conventional cultivation-based methods.
Strategic partnership with Corbion (search)
A central element of KAS's commercialisation strategy is its strategic collaboration with Corbion (search), a global leader in algae-derived ingredients and industrial fermentation. The companies are jointly advancing process optimisation, manufacturing scale-up and commercial production, combining KAS's proprietary microalgal technology with Corbion's decades of expertise in industrial biotechnology, large-scale fermentation, regulatory development and global commercialisation of ingredient solutions.
"The successful demonstration of natural astaxanthin oleoresin through dark fermentation represents a pivotal milestone," said Yves Boland, Chief Technology Officer of Corbion (search). "Corbion is delighted to continue working alongside KAS. By combining KAS's innovative biology with Corbion's expertise in strain development, industrial fermentation, product development and global market access, we believe this collaboration has the potential to significantly advance the sustainable production of natural astaxanthin."
Together, the partners are establishing a robust and globally scalable manufacturing platform that combines innovative strain technology, industrial-scale manufacturing and market access capabilities to supply premium natural astaxanthin to customers worldwide.
Investor perspective and governance
As part of the financing, Frode Sandmark, representing IVC, will join the KAS Board of Directors. IVC is the venture investment arm of Kverva, one of the world's leading investment companies within marine and aquaculture-related industries and the largest shareholder in SalMar ASA, one of the world's largest Atlantic salmon farming companies.
"KAS has developed one of the most exciting biotechnology platforms we have encountered in sustainable aquaculture," said Frode Sandmark. "Natural astaxanthin is a strategically important ingredient for salmon farming, and we see a clear opportunity for a natural, more cost-competitive, scalable and sustainable production route. KAS has demonstrated a genuine technological breakthrough with its dark fermentation platform."
Path to commercialisation
The new financing will enable KAS to expand its scientific and engineering teams, strengthen manufacturing readiness, complete regulatory programmes and engage with leading aquaculture and human nutrition companies as it prepares for commercial launch. Specific allocation of funds includes expansion of research and development capabilities, acceleration of the strategic development programme with Corbion (search), development and validation of salmon feed products, pursuit of global regulatory approvals for aquaculture and human nutrition markets, and manufacturing scale-up and commercial deployment.
KAS's platform employs proprietary non-GMO dark fermentation technology that enables efficient production of high-value natural compounds with dramatically lower land, water and resource requirements than conventional cultivation methods. The company's lead product is natural astaxanthin for aquaculture, human nutrition and animal health, with the stated ambition of transforming the economics and sustainability of one of the world's most valuable natural carotenoids.